Values as of: 2025-03-11
COMMON STOCK | Drug Manufacturers - General |
Last Closing
USD 15.6Change
-0.13 (-0.83)%Market Cap
USD 3.98BVolume
3.80MAnalyst Target
N/AVerdict
Verdict
Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding or hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
Company Website : https://www.organon.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| LLY | Eli Lilly and Company |
-5.70 (-0.69%) |
USD 781.03B |
| JNJ | Johnson & Johnson |
-1.84 (-1.10%) |
USD 401.33B |
| NVO | Novo Nordisk A/S |
-0.84 (-1.06%) |
USD 393.39B |
| ABBV | AbbVie Inc |
-3.07 (-1.42%) |
USD 340.83B |
| PFE | Pfizer Inc |
-0.65 (-2.44%) |
USD 151.49B |
| BMY | Bristol-Myers Squibb Company |
-1.60 (-2.54%) |
USD 109.38B |
| GSK | GlaxoSmithKline PLC ADR |
-0.82 (-2.03%) |
N/A |
| MRK | Merck & Company Inc |
-0.50 (-0.53%) |
N/A |
| NVS | Novartis AG ADR |
-4.12 (-3.57%) |
N/A |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| SQLV | Royce Quant Small-Cap Qua.. | 0.92 % | 0.60 % |
-0.17 (-1.03%) |
USD 0.03B |
| DES | WisdomTree U.S. SmallCap .. | 0.00 % | 0.38 % |
-0.32 (-1.03%) |
USD 2.01B |
| PSCH | Invesco S&P SmallCap Heal.. | 0.00 % | 0.29 % |
-0.03 (-1.03%) |
USD 0.19B |
| PQLC | 0.00 % | 0.00 % |
N/A |
N/A | |
| SLYV | SPDR® S&P 600 Small Cap .. | 0.00 % | 0.15 % |
-0.69 (-1.03%) |
N/A |
| VIOV | Vanguard S&P Small-Cap 60.. | 0.00 % | 0.20 % |
-0.71 (-1.03%) |
N/A |
| XPH | SPDR® S&P Pharmaceutical.. | 0.00 % | 0.35 % |
-0.45 (-1.03%) |
N/A |
| Market Performance vs. Industry/Classification (Drug Manufacturers - General) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 4.56% | 40% | F | 81% | B- | ||
| Dividend Return | 1.88% | 100% | F | 84% | B | ||
| Total Return | 6.43% | 40% | F | 85% | B | ||
| Trailing 12 Months | |||||||
| Capital Gain | -14.61% | 30% | F | 18% | F | ||
| Dividend Return | 6.13% | 100% | F | 79% | B- | ||
| Total Return | -8.48% | 30% | F | 20% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -12.07% | 10% | F | 5% | F | ||
| Dividend Return | -9.20% | 10% | F | 5% | F | ||
| Total Return | 2.87% | 50% | F | 61% | D- | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 20.30% | 40% | F | 53% | F | ||
| Risk Adjusted Return | -45.32% | 10% | F | 5% | F | ||
| Market Capitalization | 3.98B | 14% | F | 75% | C | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company has under performed its peers on annual average total returns in the past 5 years.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
This stock has shown below median revenue growth in the previous 5 years compared to its sector
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
